Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]
- Market Cap ₹ 10,100 Cr.
- Current Price ₹ 1,330
- High / Low ₹ 1,619 / 584
- Stock P/E 23.2
- Book Value ₹ 273
- Dividend Yield 0.35 %
- ROCE 26.3 %
- ROE 25.6 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 21.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.0%
- Company's median sales growth is 23.0% of last 10 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
107 | 127 | 173 | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,630 | |
96 | 105 | 137 | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,100 | |
Operating Profit | 11 | 22 | 36 | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 530 |
OPM % | 10% | 18% | 21% | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% |
3 | 2 | 4 | 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 61 | |
Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 |
Depreciation | 1 | 2 | 4 | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 48 |
Profit before tax | 11 | 22 | 36 | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 542 |
Tax % | 28% | 37% | 27% | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | |
8 | 14 | 26 | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 441 | |
EPS in Rs | 1.06 | 1.85 | 3.42 | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 57.63 |
Dividend Payout % | 38% | 27% | 23% | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 30% |
5 Years: | 22% |
3 Years: | 19% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 47% |
5 Years: | 21% |
3 Years: | 21% |
TTM: | 24% |
Stock Price CAGR | |
---|---|
10 Years: | 42% |
5 Years: | 26% |
3 Years: | 45% |
1 Year: | 113% |
Return on Equity | |
---|---|
10 Years: | 30% |
5 Years: | 28% |
3 Years: | 26% |
Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
Reserves | 18 | 28 | 47 | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,058 |
Preference Capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36 | 75 | 217 | 217 | 217 | |
7 | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 39 | 18 | 2 | 5 | 3 | |
67 | 87 | 115 | 134 | 137 | 133 | 136 | 145 | 214 | 376 | 467 | 522 | 336 | |
Total Liabilities | 107 | 135 | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,413 |
28 | 33 | 102 | 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 280 | |
CWIP | 13 | 51 | 25 | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 275 |
Investments | 1 | 1 | 0 | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 230 | 246 |
66 | 50 | 52 | 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,461 | 1,611 | |
Total Assets | 107 | 135 | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,413 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
28 | 32 | 60 | 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | 271 | |
-16 | -45 | -44 | -23 | -6 | -36 | -69 | -100 | -54 | -30 | -377 | -216 | |
-1 | -1 | -6 | -9 | -14 | -7 | -12 | 90 | 80 | -24 | -41 | -28 | |
Net Cash Flow | 10 | -15 | 10 | 19 | 23 | 25 | -14 | 73 | 70 | 215 | -81 | 27 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 25 | 2 | 0 | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 |
Inventory Days | 30 | 45 | 35 | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 |
Days Payable | 100 | 111 | 112 | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 90 |
Cash Conversion Cycle | -45 | -63 | -77 | -67 | -99 | -81 | -16 | 61 | 251 | 166 | 138 | 166 |
Working Capital Days | -143 | -176 | -181 | -128 | -114 | -29 | 47 | 104 | 167 | 152 | 166 | 159 |
ROCE % | 31% | 52% | 64% | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2m - Press release regarding grant of final from the USFDA for ANDA Ketorolac tromethamine Ophthalmic Solution 0.5% is attached herewith
- Commencement Of Operations By Caplin One Labs Limited, Wos Of The Company 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 22 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 27 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT REC
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptPPTREC
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Oct 2019TranscriptPPT
Product Portfolio[1]
Presently, the company has a very wide portfolio of pharma products with 4,000+ registered products, 650+ formulations and presence in 36 therapeutic segments. It has minimal reliance for revenues on a single product/ therapeutic segment.